Long Term Follow Up of Sub-retinal Transplantation of hESC Derived RPE Cells in Stargardt Macular Dystrophy Patients

Completed

Conditions studied: Stargardt's Macular Dystrophy

In brief

The purpose of this study is to evaluate the long term safety and tolerability of MA09-hRPE cellular therapy in patients with advanced Stargardt's Macular Dystrophy (SMD) from one to five years following the surgical procedure to implant the MA09-hRPE cells.

Key facts

Study ID

NCT02445612

Run by

Astellas Institute for Regenerative Medicine

People needed

13

Starts

2012-07-11

Expected to finish

2019-06-21

Last updated by the study team

2024-10-31

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Must have been treated with hESC-RPE cell transplant in the core protocol.
• Able to understand and willing to sign the informed consent to participate in the follow-up study.

You may not qualify if…

• There are no exclusion criteria

Where it is running

• Jules Stein Eye Institute, UCLA School of Medicine — Los Angeles, California, United States
• Bascom Palmer Eye Institute — Miami, Florida, United States
• Wills Eye Institute-Mid Atlantic Retina — Philadelphia, Pennsylvania, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.